thioglucosoaurate
Aurothioglucose (trade name Solganal), also known as gold thioglucose, is a glucose derivative formerly used to treat rheumatoid arthritis, that cannot be adequately controlled by other medicines. Aurothioglucose has been shown to inhibit protein kinase C, a metalloenzyme containing Zn(2+) bound to cysteine and histidine residues, which plays a crucial role in intracellular signal transduction by phosphorylating serine/threonine residues in the protein. The inhibition of protein kinase C has been suggested as a possible mode of action for the therapeutic antirheumatic action of gold drugs. In 2001, aurothioglucose was withdrawn from the Dutch market, where it had been the only injectable gold preparation available since 1943, forcing hospitals to change medication for a large number of patients to aurothiomalate. The drug had been in use for more than 70 years, and four years later the reasons for its sudden disappearance remained unclear. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Indications
Approved for
Mechanism of action
- Thioredoxin reductase 1INHIBITOR
TXNRD1 inhibitor
IC50 = 65 nm
Chemistry & pharmacology
SMILES
[Au+].OC[C@H]1O[C@H]([S-])[C@H](O)[C@@H](O)[C@@H]1O- Mol. weight
- 392.18 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- NCATS2P2V9Q0E78 ↗
- ChEMBLCHEMBL2354773 ↗
- ChEMBLCHEMBL1697725 ↗
- ChEMBLCHEMBL1189679 ↗
Also known as
- aureotan
- aureotan 100
- auromyose
- auromyose
- aurothioglucose
- aurothioglucose
- aurothioglucose
- aurothioglucose
- aurothioglucose
- aurothioglucose
- gold thioglucose
- gold thioglucose
- gold thioglucose
- gold thioglucose
- solganal
- solganal
- thioglucosoaurate